AI Article Synopsis
- Groups of lean, obese, and obese-non-insulin-dependent diabetic rats were given the a-glucosidase inhibitor Miglitol in their diet between 8 and 15 weeks of age.
- The obese rats showed greater weight gain and other adverse health parameters than lean rats, but Miglitol treatment improved certain enzyme activities and glycemic parameters especially in obese rats.
- The findings suggest that Miglitol can enhance insulin sensitivity and glycemic control at lower doses, but higher doses or prolonged treatment may be necessary for better results on body fat and lipid levels.
Article Abstract
1. Groups of lean, obese, and obese-non-insulin-dependent diabetic LA/N-cp and SHR/N-cp rats were administered the a-glucosidase inhibitor Miglitol (150 mg/kg diet, ad libitum) from 8 until 15 weeks of age. 2. Phenotype effects (obese greater than lean) were present for weight gain, adiposity, serum glycemic and lipid parameters, and for liver glucokinase, glucose-6-phosphate dehydrogenase, and malic enzyme activity. Miglitol treatment was associated with improvements in glucokinase and malic enzyme in both strains, and in improvements in glycemic parameters in obese rats. 3. These results are consistent with variable improvements in glycemic control and insulin action following low dose Miglitol treatment, and indicate that indirect effects of the drug on insulin sensitivity in peripheral tissues and on glucoregulatory enzymes may contribute to the glycemic improvements observed with this drug, while greater dosages or longer treatment may be required to observe comparable improvements in adiposity or plasma lipid profiles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0742-8413(91)90105-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!